DPT Laboratories has received approval from the FDA to manufacture commercial supplies of Healthpoint’s Collagenase Santyl sterile ointment for wound care at its Center of Excellence for Sterile and Specialty Products in Lakewood, NJ. Healthpoint will begin shipment of commercial lots of Santyl Ointment this month.
“We are very excited to achieve this important milestone,” said Travis E. Baugh, president and chief operating officer of Healthpoint. “DPT and Healthpoint have had a long and mutually beneficial relationship over the years, with DPT having been our preferred manufacturing partner on a variety of products. The recent FDA approval of DPT’s Lakewood facility to produce Collagenase Santyl Ointment allows Healthpoint to immediately double its production capacity, thereby helping assure continuous, uninterrupted supply for this important therapeutic agent.”
“Our team in Lakewood has executed this project from the ground up and demonstrated a solid commitment to best practices in developing and commercializing sterile products,” said Gene Ciolfi, DPT’s general manager for Sterile & Specialty Products. “Receiving FDA approval to manufacture this leading wound care product underscores our commitment to serve the healthcare community and improve patient health and quality of life.”
DPT’s Sterile & Specialty Products center focuses on aseptic production of sterile dosage forms to include small-volume parenterals, ophthalmic preparations, preservative-free nasal sprays and sterile ointments. Santyl is the third commercial approval for the Lakewood facility since the launch of its full-scale sterile operation in early 2010.
Click here to learn more about DPT